Symbicort SMART (Symbicort Maintenance And Reliever Therapy)
Information source: AstraZeneca
Information obtained from ClinicalTrials.gov on August 08, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Asthma
Phase: N/A
Status: Recruiting
Sponsored by: AstraZeneca Official(s) and/or principal investigator(s):
Joon-Woo Bahn, Study Director, Affiliation: AstraZeneca Korea
Overall contact:
AstraZeneca Korea Clinical Study, Information, Phone: 0082-2-2188-2145, Email: yookyung.kim@astrazeneca.com
Summary
The purpose of this study is to investigate the extent of Symbicort use in patients
prescribed Symbicort as maintenance and reliever therapy.
Clinical Details
Official title: SMART (Symbicort Maintenance And Reliever Therapy): Reassure Program for Patients Using Symbicort Turbuhaler as Maintenance and Reliever Therapy in Korean Clinical Practice
Study design: Prospective
Eligibility
Minimum age: 12 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Asthma patients prescribed Symbicort as maintenance and reliever therapy, according to
the label, before inclusion in this program.
Exclusion Criteria:
- Since this programme intends to describe Symbicort use in routine clinical practice
when prescribed as Symbicort maintenance and reliever therapy, there are no programme
specific exclusion criteria, other than: involvement in the planning and conduct of
the programme (applies to both AstraZeneca staff or staff at the investigational
site)
Locations and Contacts
AstraZeneca Korea Clinical Study, Information, Phone: 0082-2-2188-2145, Email: yookyung.kim@astrazeneca.com
Research Site, Seoul, Jongro-gu, Korea, Republic of; Recruiting
Research Site, Seoul, Kangnam-gu, Korea, Republic of; Recruiting
Research Site, Seoul, Songpa-gu, Korea, Republic of; Recruiting
Additional Information
Starting date: July 2007
Last updated: October 17, 2007
|
